The Delphi consensus and other published evidence. An aging population. Cancer incidence and prevalence are increasing. Technology evolves. Ablation continues to grow due to all these factors and more.

We are excited for what will be the most impactful CIRSE yet - and again share here our presence as well as the scientific highlights of the congress. 

As we have grown over the years - so does our booth space. Once again, we will have two CAS-One IR systems present to give plenty of rich, hands-on experiences to interested physicians. We did this at CIRSE Barcelona last year, after the previous ECIO and CIRSE we had to force people to wait to try out CAS-One IR for themselves. This has been a welcome "problem" for us.

From a technology standpoint, this year we will be focusing on AblaFuse - our Automatic Fusion that launched early in the summer and has already supported hundreds of cases.

No longer will organ movement - for whatever reason - or tissue deformation disrupt a treatment plan, needle verification, or most importantly, an ablation confirmation. With little physician input, CAS-One IR will fuse images to ensure procedural accuracy is kept in all phases of the Quality Ablation workflow. Come by to see it for yourself - consider bringing a dataset to Copenhagen (pre and post contrast enhanced CT) and AblaFuse yourself.

See our full landing page dedicated to the release here

While at ECIO there are routinely 10+ abstracts focusing on CAS-One IR, generally at CIRSE there are fewer - we are eager to see what emerges - and will update this blog post prior to the event with the relevant posters if they are released ahead of time

Of course, on the Monday evening, we are hosting our annual Scientific Dinner and afterparty - the scientific portion is led by CASCINATION's founder and CEO, Stefan Weber, and features presentations from Dr. Shaheen Noorani (UK) and Dr. Jonathan Kessler (USA). Dr. Noorani will feature her latest research, showing an astonishingly low LTP, and Dr. Kessler will present how CAS-One IR has drastically changed the tumor ablation program at his hospital (City of Hope). Please contact your local CASCINATION representative for an invitation as space is limited. 

After the dinner discussions finish, we will again welcome DJ Quality Ablation and continue into the night!

Finally - every year we analyze the agenda and call out what we believe to be the most interesting topics - please see below for our guide to "can't miss" sessions focused on ablation.

Also, note side topics such as "Patient management: how to get referrals" as well as "Shifting from procedure focus to IR therapies and treatments", and a Film Interpretation Quiz, and more.

The full highlights are below - we will see you there.

Saturday September 5^th

IR 126 – IR beyond interventions 10:00-11:00 Auditorium 11

126.1 Patient management: how to get referrals - M. Little

ERT 135 –Complications: dealing with the aftermath 11:30-12:30 Auditorium 12

135.1 Informed consent: why it’s important and how to do it effectively - E. Keller

135.2 Difficult conversations: how to speak with patients and relatives after a complication - N. McEniff

135.4 Learning from complications: how to conduct effective M&M meetings - F. Wolf

FC 162 - Renal Cancer 16:15-17:15 Auditorium 3

 162.1 Building an RCC practice  – P. Haslam

 162.2 Must know literature in RCC ablation: an update - O. Graumann

 162.3 Tumour tailored approach - T. Atwell

 162.4 Tips and tricks for avoiding complications - C. Georgiades

 BTL 164 – Percutaneous ablation  16:15-17:15 Room 20

 164.1 Basic and emerging ablative therapies - H. Scheffer

 164.2 Preventing complications in thermal ablation -M.Gkeli

 SP 176 – Non-thermal ablation  17:30-18:30 Room 19

 176.1 Irreversible electroporation for colorectal liver metastases: long-term outcomes from a transatlantic multicenter study - S. Van der Lei

 176.2 Irreversible electroporation for hepatocellular carcinoma: explant-based ground truth of local efficacy and MRI response -C. Sorce

 176.3 Ice nanonucleator-enhanced cryoablation improves perivascular ablation efficacy: phantom and porcine liver model study - D. Kim

 176.4 Percutaneous electrochemotherapy for liver malignancies: early insights from the European prospective registry, RESPECT - A. Kovacs 

Sunday September 6^th

 FS 215  Percutaneous ablation for benign indications  – 8:30-9:30 Auditorium 10

215.3 Benign bone tumours: ablation as first-line treatment - M. Moussa

215.5 Ablation options in children - M. Temple

 FS 216 – CIRSE vision: Shaping the future of interventional radiology  – 8:30-9:30 Auditorium 11

 216.1 The CIRSE Vision: three priorities, one goal - C. Binkert

 216.3 Shifting from procedure focus to IR therapies and treatments - T. Kroencke

 FS 212 – Lung ablation - 8:30-9:30 Auditorium 15

212.1 Must know literature in the NSCLC percutaneous ablation: an update - R. Goh

212.2 Literature update for percutaneous ablation in oligometastatic disease  - E. Faiella

212.3 Imaging-guided precision  - M. van Strijen

 212.5 Lung ablation quality assurance - A. Tam

 IRT 227 – Future treatments and innovations in IR 10:00-11:00 Auditorium 11

 227.2 Future IO technologies - T. Auer

 227.4 Future MSK IR technologies - V. Peric

 CS 222 – Local cure for lung tumours 10:00-11:00 Auditorium 15

 222.2 Early-stage NSCLC: percutaneous ablation -  P. Cavalcante Viana

 222.4 Oligometastatic disease: percutaneous ablation - J. Gaubert

 222.6 SBRT failures: percutaneous ablation - J. Palussiere

 FIQ 251 – Film Interpretation Quiz  14:30-15:15 - Auditorium 1

 ERT 262 – Pancreatico-biliary cancer 16:15-17:15 Auditorium 11

 262.1 Percutaneous ablation for intrahepatic cholangiocarcinoma  - T. Inchingolo

 SPH 269b – AI in IR: Who is responsible when the algorithm errs? 16:15-17:00 News on Stage

 269b.1 Legal questions regarding AI in IR  - T. Ali

 269b.4 AI-driven real-time prediction of interventional radiology complications aligned with SIR and CIRSE patient safety sops: a four-year hospital-wide training study - M. Gupta

 SP 267 – Thermal ablation 16:15-17:15 Room 19

 267.1 Long-term survival outcomes of thermal ablation, transarterial radioembolization and resection for localized hepatocellular carcinoma in real world patients: a SEER database propensity score matched study - D. Chlorogiannis

 267.3 Thermal ablation versus surgical resection for intermediate-size (3–5 cm) colorectal liver metastases: results from the Amsterdam colorectal liver met registry (AmCORE) - M. Dijkstra

 267.4 Validation of a cross-modality automatic image registration system for intraoperative CRLM localization in CT-guided ablation: a dual-center retrospective study - X. Wu

Monday September 7^th

 FS 313 – Musculoskeletal interventional oncology – 8:30-9:30 Auditorium 2

 313.1 Spine ablation which tumour which ablative therapy - R. Cazzato

 313.3 Spine electrochemotherapy: tips and tricks for avoiding complications - F. Deschamps

 313.4 Soft tissue sarcomas managing recurrences - S. Tutton

 SPH 328 – How can AI make my life easier?  - 10:00-11:05 News of Stage

 328.1 AI in IR: what is the promise, and what actually works? - S. Solomon

 328.7 Feasibility of generative AI for CT-guided liver biopsy trajectory planning: a pilot study - I. Echelman

 SPH 369 – Training the next generation of interventional radiologists in the AI era - 16:15-17:15 News on Stage

 369.1 Interventional radiology in 2036 F. Cornelis

 369.2 How is AI going to affect training and education for next generation IRs? - L. Saccenti

 369.3 LLM - friend or foe for developing clinical IR? K. Fung

 MPJ 372 – Neuroendocrine tumours 17:30-18:30 Auditorium 15

 372.1 Why NETs are unique: indolent but metastatic - A. Koumarianou

 372.5 Decision-making: when to ablate, when to embolize, when to observe - L. Tselikas

CAS-One IR - Scientific Dinner - 19:15 - 22:00 - 1250 Indre By - Copenhagen

S. Weber, S. Noorani, J. Kessler

Tuesday September 8^th

 FS 424 – HCC: integrating IO therapies in the multidisciplinary pathway - 10:00-11:00 Auditorium 15

 424.1 BCLC 2025 updates - M. Sanduzzi Zamparelli

 424.2 / Ablation and TARE: patient selection in early-stage HCC - S. Young

 SPH 428 – Robotics and human–machine interaction 10:00-11:00 News on Stage

 428.1 What does robotics really add — and where does it stop? - U. Koç 

 428.3 How effectively does robotics mitigate operator radiation exposure? - M. Besler 

 428.4 Robotics in interventional oncology : the value of collaborative controls - Y. Le Meur 

 428.5 Development of a custom 7-dof robotic prostate fusion biopsy system utilizing 3-point volumetric co-registration: technical description and initial clinical validation - A. Aktas 

 MC 441 – Meet the CVIR authors 2 – Ablation 13:00-1400 News on Stage

 441.1 / Intratumoural contrast tagging during CT-hepatic arteriography-guided microwave ablation of colorectal liver metastases (t-CTHA) to enhance tumour targeting and margin assessment - S. Van der Lei

 441.2 / Impact of tumor size on outcomes of hepatic arteriography and C-arm CT-guided ablation (HepACAGA): > 3 cm is no absolute contraindication - N. Wijnen

 441.3 / Microwave ablation of colorectal pulmonary metastases offers excellent local tumor control and can prolong time off chemotherapy - T. Cooke

 441.5 / Risk factors for residual unablated tumour following CT-guided percutaneous renal cryoablation: lessons from the EuRECA registry - E. de Kerviler

 CS 465 – Local cure for colorectal liver metastases - 16:15-17:15 Auditorium 15

 465.1 Ablation for small CLM: time to replace surgery: con - A. Fretland

 465.2 Ablation for small CLM: time to replace surgery: pro - M. Meijerink

Wednesday September 9^th

 ERT 512 – Ablation margins - 8:30-9:30 Auditorium 15

 512.1 Clinical need and literature evidence - O. Moschovaki-Zeiger 

 512.2 Methodology, software and status - M. Calandri

 512.3 Challenges for widespread adoption - B. Odisio

 512.4 Ablation margin status as a valid imaging biomarker - E. Johnston

 FS 522 – Advanced imaging navigation 10:00-11:00 Auditorium 11

 522.5 Robotic navigation: what is currently missing? - B. Wood